OssDsign Shifts to Pure Play Orthobiologics

OssDsign is undertaking a strategic shift to focus operations on its orthobiologics business in the U.S.

The company will focus on its nanosynthetic bone graft OssDsign Catalyst, an off-the-shelf product characterized by high scalability. All activities pertaining to the company’s OssDsign Cranial PSI patient-specific cranial implant business...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us